Clinical Trial Update: AURA-IPF: A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of AP02 (Nintedanib Solution) in IPF [Phase 2]

View source ↗

Summary

A Phase 2 randomized study is evaluating the safety and efficacy of AP02 (Nintedanib Solution) in idiopathic pulmonary fibrosis and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pulmonary Fibrosis

Drugs mentioned

• AP02 (Nintedanib Solution) (Nintedanib)

Snippet

Sponsor: Avalyn Pharma Inc. | Conditions: Idiopathic Pulmonary Fibrosis (IPF) | Phase 2 | Status: RECRUITING